Effectiveness of Target Therapy and its Complications in the Treatment of Polyangiitis Granulematosis
Keywords:
granulomatosis with polyangiitis, target therapy, complicationsAbstract
In the treatment of polyangiitis granulomatosis (PAG), the selective recommendation of gene-engineered biological drugs, the application of a combination of glucocorticoids and immunodepressants allow to increase the effectiveness of treatment and have a positive effect on the outcome of the disease. Early detection of PAG progression and complications, at the same time, assessment of important connections between clinical, biochemical and immunological manifestations of the disease, analysis of effective treatment methods and alternatives are of particular importance.
Despite many scientific researches conducted in different countries of the world, diagnosis and treatment of PAG, development of principles for predicting the complications and consequences of the disease, and identification of markers of negative consequences remain an urgent problem.
References
Gibb W. et al., 1986 Gibb W, Wiliams A. Nocardiosis mimicking Wegener's granulomatosis. Scand J Infect Dis 1986; 18:583-585.
Gibson A. The epidemiology of Wegener’s granulomatosis and microscopic polyangiitis in a Southern Hemisphere region / A. Gibson [et al.] // Rheumatology (Oxford). — 2006. — Vol. 45. — № 5. — Р. 624–628.
Greco A. Clinic manifestations in granulomatosis with polyangiitis / A. Greco [et al.] // International journal of immunopathology and pharmacology. — 2016. — Vol. 29. — № 2. — Р. 151–159.
Groot K. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody–associated vasculitis. A randomized trial / K. Groot [et al.] // Annals of internal medicine. — 2009. — Vol. 150. — № 10. — Р. 670–680.
Girard C. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener's): a report on 26 cases / C. Girard [et al.] // Medicine (Baltimore). — 2015. — Vol. 94. — № 32. — Р. e1088.
Guerry M. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis / M. Guerry [et al.] // Rheumatology (Oxford). — 2012. — Vol. 51. — № 4. — Р. 634–643.
Guillevin L. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis / L. Guillevin [et al.] // Arthritis and rheumatism. — 1997. — Vol. 40. — № 12. — Р. 2187–2198.
Guillevin L. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort / L. Guillevin [et al.] // Medicine (Baltimore). — 2011. — Vol. 90. — № 1. — Р. 19–27.
Guillevin L. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral, 188 188. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. NEJM 2014;371(19):1771-80.
Harper L. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up / L. Harper [et al.] // Annals of the rheumatic diseases. — 2012. — Vol. 71. — № 6. — Р. 955–60.
Harper S.L., et al. Wegenerґs granulomatosis: the relationship between ocular and systemic disease J. Rheumatol. 2001. – №28. – P.1025−1026.
Hellmich B. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis / B. Hellmich [et al.] // Annals of the rheumatic diseases. — 2007. — Vol. 66. — № 5. — Р. 605–617.
Hermann J. Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall / J. Hermann [et al.] // Annals of the rheumatic diseases. — 2005. — Vol. 64. — № 4. — Р. 641–643.
Hernández-Rodríguez J. Surgical Interventions and Local Therapy for Wegener's Granulomatosis / J. Hernández-Rodríguez, G. Hoffman, С. Koening // Current opinion in rheumatology. — 2010. — Vol. 22. — № 1. — Р. 29–36.
Hoffman G. S. Wegener granulomatosis: An analysis of 158 patients / G. S. Hoffman [et al.] // Annals of internal medicine. — 1992. — Vol. 116. — № 6. — Р. 488–498.
Holle J.U. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? vasculitides / J. U. Holle [et al.] // Annals of the rheumatic diseases. — 2010. — Vol. 69. — № 11. — Р. 1934–1939.
Holle J.U., Windmöller M., Lange C., Gross W.L., Herlyn K., and Csernok E. Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis. // Rheumatol. Oxf. Engl. 2013. – P.257-266
Holle J.U., Gross W.L., Latza U., Nölle B., Ambrosch P., Heller M., et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. // Arthritis Rheum 2011. – №63. – P.257-66.
Holle J.U. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations / J. U. Holle [et al.] // Annals of the rheumatic diseases. — 2012. — Vol. 71. — № 3. — Р. 327–333.
Hu W. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement / W. Hu [et al.] // Nephrology, dialysis, transplantation. — 2008. — Vol. 23. — № 4. — Р. 1307–1312.
Hoffman G. S. Wegener granulomatosis: An analysis of 158 patients / G. S. Hoffman [et al.] // Annals of internal medicine. — 1992. — Vol. 116. — № 6. — Р. 488–498.
Holle J.U. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: does it occur as persistent disease stage? vasculitides / J. U. Holle [et al.] // Annals of the rheumatic diseases. — 2010. — Vol. 69. — № 11. — Р. 1934–1939.
Holle J.U., Windmöller M., Lange C., Gross W.L., Herlyn K., and Csernok E. Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis. // Rheumatol. Oxf. Engl. 2013. – P.257-266
Hugle B. et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener’s granulomatosis. // Arthritis Care Res. 2010. – №62. – P.1661–1664.
IANNELLA G. et al. Granulomatosis with polyangiitis and facial palsy: Literature review and insight in the autoimmune pathogenesis. Autoimmun Rev, v. 15, n. 7, p. 621-31, Jul 2016. ISSN 1873-0183 (Electronic) 1568-9972 (Linking). Available at: <
https://www.ncbi.nlm.nih.gov/pubmed/26851550 >
Jagiello P. New genomic region for Wegener’s granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes / P. Jagiello [et al.] // Human genetics. — 2004. — Vol. 114. — № 5. — Р. 468–477.
Jayne D Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity / D. Jayne [et al.] // The Quarterly journal of medicine. — 2000. — Vol. 93. — № 7. — Р. 433–439.
Jayne D Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis / D. Jayne [et al.] // Journal of the American Society of Nephrology. — 2007. — Vol. 18. — № 7. — Р. 2180–2188.
Jones R. A randomised trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: “MYCYC”. On behalf of the European vasculitis study group / R. Jones, M. Walsh // La Presse Médicale. — 2013. — Vol. 42. — № 4. — Р. 678–679.
Jones R.B. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. / R. B. Jones, [et al.] // The New England journal of medicine. — 2010. — Vol. 363. — № 3. — Р. 211–220. . 26. — № 10. — Р. 3077–3079.
Kallenberg C.G. Key advances in the clinical approach to ANCA-associated vasculitis / C. G. Kallenberg // Nature Reviews Rheumatology. — 2014. — Vol. 10. — № 8. — Р. 484–493.
Kamali S., Erer B., Artim-Esen A., Gul A., Ocal L., Konice M., Aral O., and Inanc M. Predictors of Damage and Survival in Patients with Wegener's Granulomatosis: Analysis of 50 Patients. // J Rheumatol 2010. – №37. – P.374–8; doi:10.3899/jrheum.090387
Kessenbrock K. Netting neutrophils in autoimmune small vessel vasculitis / K. Kessenbrock [et al.] // Nature Medicine. — 2009. — Vol. 15. — № 6. — Р. 623–625.
Kitching A.R., Anders H-J., Basu N., et al. ANCA-associated vasculitis. Nat Rev Dis Prim. 2020. – №6. – P.71.
Knecht K., Mishriki Y.Y. More than a mouth ulcer: oral ulcer due to Wegener's granulomatosis. Postgrad Med 1999. – №105. – P.200-203.
Knight A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide / A. Knight [et al.] // Annals of the rheumatic diseases. — 2004. — Vol. 63. — № 10. — Р. 1307–1311.
Klemmer P.J. Plasmapheresis Therapy for Diffuse Alveolar Hemorrhage in Patients with Small-Vessel Vasculitis / P. J. Klemmer [et al.] // American journal of kidney diseases. — 2003. — Vol. 42. — № 6. — Р. 1149–1153.
